0000000000129060

AUTHOR

Rosaria Talarico

0000-0003-4268-9611

showing 4 related works from this author

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated perio…

2015

Abstract TNFR-associated periodic syndrome is an autoinflammatory disorder caused by autosomal-dominant mutations in TNFRSF1A, the gene encoding for TNFR superfamily 1A. The lack of knowledge in the field of TNFR-associated periodic syndrome biology is clear, particularly in the context of control of immune self-tolerance. We investigated how TNF-α/TNFR superfamily 1A signaling can affect T cell biology, focusing on conventional CD4+CD25− and regulatory CD4+CD25+ T cell functions in patients with TNFR-associated periodic syndrome carrying either high or low penetrance TNFRSF1A mutations. Specifically, we observed that in high penetrance TNFR-associated periodic syndrome, at the molecular le…

Male0301 basic medicinePenetranceAutoimmunitymedicine.disease_causeT-Lymphocytes RegulatoryImmune toleranceSettore MED/38 - Pediatria Generale E SpecialisticaTRAPS; Tconvs; Tregs; autoimmunity; immune toleranceImmunology and AllergyIL-2 receptorChildGeneticsMutationTconvTOR Serine-Threonine Kinaseshemic and immune systemsMiddle AgedAcquired immune systemPenetranceTregSTAT Transcription Factorsmedicine.anatomical_structureReceptors Tumor Necrosis Factor Type ICytokinesFemalebiological phenomena cell phenomena and immunitySignal TransductionAdultAdolescentFeverT cellAutoimmunity; Immune tolerance; Tconvs; Tregs; TRAPS; Cell Biology; ImmunologyImmunologyReceptors Antigen T-CellContext (language use)Tregs[object Object]BiologyImmunophenotypingYoung Adult03 medical and health sciencesImmune systemmedicineHumansAgedCell ProliferationDemographyTconvsImmune toleranceHereditary Autoinflammatory DiseasesTRAPSCell Biologybiological factors030104 developmental biologyMutationCancer research
researchProduct

Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.

2019

Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients. Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and the concomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events l…

Settore MED/38 - Pediatria Generale E SpecialisticaAnakinraSettore MED/16 - REUMATOLOGIAAnakinra Systemic Juvenile Idiopathic Arthritis Still’s disease
researchProduct